Literature DB >> 14608121

Diet and cancer: what's next?

David Kritchevsky1.   

Abstract

Our advances in knowledge of the epidemiology of cancer and of the nutritional and genetic effects on this disease have not yet been translated into successful treatment. This is due in part to our tendency toward reductionist thinking, dating to the days when one drug killed one bug. We could learn something by trying to reconcile the differences. Cancer is a degenerative disease that develops over a long time and goes through many stages. Perhaps different nutritional approaches are needed at each stage. The same dietary treatment may not exert the same effects during all stages of tumor development. Obesity is one risk factor that is generally agreed upon. Energy (caloric) restriction has been shown to inhibit experimental carcinogenesis, and energy expenditure affects human carcinogenesis. It would be interesting to combine energy restriction with nutritional treatment. One neglected area of inquiry is that of interactions among nutrients. Substitution of nutrient A for nutrient B can precipitate a series of interactions between nutrient B and the rest of the diet. If more experimental work were done with spontaneous tumors, it would eliminate possible effects of carcinogen metabolism in carcinogenesis and might provide a more accurate reflection of human carcinogenesis. Focusing on one specific dietary component or class of components belies the complexity of the problem.

Entities:  

Mesh:

Year:  2003        PMID: 14608121     DOI: 10.1093/jn/133.11.3827S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  8 in total

Review 1.  The role of adiponectin signaling in metabolic syndrome and cancer.

Authors:  Michael P Scheid; Gary Sweeney
Journal:  Rev Endocr Metab Disord       Date:  2014-06       Impact factor: 6.514

2.  A nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial.

Authors:  Michele L Mietus-Snyder; Mark K Shigenaga; Jung H Suh; Swapna V Shenvi; Ashutosh Lal; Tara McHugh; Don Olson; Joshua Lilienstein; Ronald M Krauss; Ginny Gildengoren; Joyce C McCann; Bruce N Ames
Journal:  FASEB J       Date:  2012-05-01       Impact factor: 5.191

3.  Caloric restriction mimetic 2-deoxyglucose antagonizes doxorubicin-induced cardiomyocyte death by multiple mechanisms.

Authors:  Kai Chen; Xianmin Xu; Satoru Kobayashi; Derek Timm; Tyler Jepperson; Qiangrong Liang
Journal:  J Biol Chem       Date:  2011-04-26       Impact factor: 5.157

4.  Antioxidant defense markers modulated by glutathione S-transferase genetic polymorphism: results of lung cancer case-control study.

Authors:  Edyta Reszka; Wojciech Wasowicz; Jolanta Gromadzinska
Journal:  Genes Nutr       Date:  2007-10-16       Impact factor: 5.523

5.  Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.

Authors:  Lizzia Raffaghello; Changhan Lee; Fernando M Safdie; Min Wei; Federica Madia; Giovanna Bianchi; Valter D Longo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-31       Impact factor: 11.205

Review 6.  Weight control and cancer preventive mechanisms: role of insulin growth factor-1-mediated signaling pathways.

Authors:  Linglin Xie; Weiqun Wang
Journal:  Exp Biol Med (Maywood)       Date:  2013-02

7.  Safety and feasibility of fasting in combination with platinum-based chemotherapy.

Authors:  Tanya B Dorff; Susan Groshen; Agustin Garcia; Manali Shah; Denice Tsao-Wei; Huyen Pham; Chia-Wei Cheng; Sebastian Brandhorst; Pinchas Cohen; Min Wei; Valter Longo; David I Quinn
Journal:  BMC Cancer       Date:  2016-06-10       Impact factor: 4.430

8.  Amino Acid Starvation Sensitizes Resistant Breast Cancer to Doxorubicin-Induced Cell Death.

Authors:  Mark Thomas; Tanja Davis; Theo Nell; Balindiwe Sishi; Anna-Mart Engelbrecht
Journal:  Front Cell Dev Biol       Date:  2020-10-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.